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Background
All current human immunodeficiency virus (HIV) vaccine
candidates contain multiple viral components and elicit
antibodies that react positively in licensed HIV diagnostic
tests. Thus, vaccine trial participants could be falsely diag-
nosed as infected with HIV and it is a major public health
concern for volunteers who want to participate in future
HIV vaccine trials. Additionally, uninfected, seropositive
vaccinees may encounter long-term social and economic
harms. Moreover, this also interferes with early detection
of true HIV infections during preventive HIV vaccine tri-
als. Based on the increased number of HIV vaccines being
tested globally, it is essential to differentiate vaccine –
from virus-induced antibodies.
Methods
Using a whole-HIV-genome phage display library, we
identified conserved sequences in Env-gp41 and Gag-p6
which are recognized soon after infection, do not contain
protective epitopes, and are not part of most current HIV
vaccines. We established a new HIV-serodetection assay
termed HIV-SELECTEST was developed based on these
peptides that distinguishes between vaccine-induced anti-
bodies and seroconversion following HIV infections.
Results
The HIV-SELECTEST performed at >99% specificity and
sensitivity. Importantly, using seroconversion panels col-
lected from plasma donors early after HIV infection
(CHAVI), and from male and female enrollees in the AIE-
DRP, CAPRISA and ZEHRP cohorts, the HIV-SELECTEST
detected HIV antibodies within 2–4 weeks of RNA detec-
tion, and performed similarly to currently FDA-licensed
tests. A rapid test version of the SELECTEST assay has been
developed. This rapid test performs at a comparable level
of specificity and sensitivity to the EIA version of the HIV-
SELECTEST. Importantly, in testing of plasma samples
from multiple HIV vaccine trials, uninfected trial partici-
pants scored negative, while all intercurrent infections
were detected within 1 to 3 months of HIV infection.
Conclusion
Thus both versions of the HIV-SELECTEST are simple but
robust diagnostic tools for easy implementation in HIV
vaccine trials and blood banks worldwide.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P192 doi:10.1186/1742-4690-6-S3-P192
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P192
© 2009 Khurana et al; licensee BioMed Central Ltd. 